China SXT Pharmaceuticals, Inc. (SXTC)

Every figure this model derived for SXTC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,023 PaymentsToAcquirePropertyPlantAndEquipment 2025-03-31
cash 28,175,865 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 34,509,722 AssetsCurrent 2026-03-31
current liabilities 4,349,320 LiabilitiesCurrent 2026-03-31
equity 29,707,422 StockholdersEquity 2026-03-31
interest expense 62,965 InterestExpenseNonoperating 2026-03-31
ocf -4,017,456 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 1,138,052 RevenueFromContractWithCustomerIncludingAssessedTax 2026-03-31
sbc 5,305,739 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up SXTC on one particular measure came for.

RatioValue
cash operating margin-153.2
current ratio8.13
current ratio reported7.93
deferred revenue growth78.11
dilution pct7083.47
fcf margin-353.19
interest cover-113.13
operating margin-625.89
owner earnings margin-819.4
revenue growth-34.63
revenue growth per share-99.09
roic-258.07
rule of 40-660.52
sbc pct revenue466.21

What to be careful about

What this model itself distrusts about SXTC's figures. Written by the derivation as it ran, not added afterwards.